CytRx Corporation (CYTR): Price and Financial Metrics


CytRx Corporation (CYTR): $0.14

0.01 (+3.70%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CYTR to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CYTR Stock Price Chart Interactive Chart >

Price chart for CYTR

CYTR Price/Volume Stats

Current price $0.14 52-week high $4.70
Prev. close $0.14 52-week low $0.09
Day low $0.13 Volume 14,700
Day high $0.14 Avg. volume 132,593
50-day MA $0.20 Dividend yield N/A
200-day MA $0.47 Market Cap 6.09M

CytRx Corporation (CYTR) Company Bio


CytRx Corporation operates as a biopharmaceutical research and development company specializing in oncology. The company was founded in 1985 and is based in Los Angeles, California.


CYTR Latest News Stream


Event/Time News Detail
Loading, please wait...

CYTR Latest Social Stream


Loading social stream, please wait...

View Full CYTR Social Stream

Latest CYTR News From Around the Web

Below are the latest news stories about Cytrx Corp that investors may wish to consider to help them evaluate CYTR as an investment opportunity.

CytRx Comments on Orphazyme's Update on European Union Regulatory Review of Arimoclomol in Niemann-Pick Disease Type C

LOS ANGELES, February 24, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today commented on Orphazyme A/S's (NASDAQ: ORPH) ("Orphazyme") announced update on the ongoing review of the Marketing Authorisation Application for its investigational product candidate, arimoclomol, for the treatment of Niemann-Pick disease type C ("NPC") by the Committee for Medic

Yahoo | February 24, 2022

CytRx Highlights Orphazyme's Update on Planned NDA Resubmission for Arimoclomol in Niemann-Pick Disease Type C

LOS ANGELES, February 14, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today highlighted Orphazyme A/S's (NASDAQ: ORPH) ("Orphazyme") announced update on the process and anticipated timelines for resubmission of its New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") for its investigational product candidate, arimoclomol, for th

Yahoo | February 14, 2022

CytRx to Hold Town Hall for Stockholders on Thursday, January 20th

LOS ANGELES, January 18, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that it will hold a town hall for stockholders on Thursday, January 20, 2022 at 4:30 PM Eastern. The town hall will be led by the Company’s Chief Executive Officer, Dr. Stephen Snowdy, and include a question-and-answer session. The town hall can be accessed

Yahoo | January 18, 2022

CytRx to Participate in the H.C. Wainwright BioConnect Virtual Conference

LOS ANGELES, January 07, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that John Caloz, the Company’s Chief Financial Officer, is scheduled to present at the H.C. Wainwright BioConnect Virtual Conference, which is taking place virtually from Monday, January 10th through Thursday, January 13th.

Yahoo | January 7, 2022

CytRx Announces the Appointment of Dr. Stephen Snowdy as Chief Executive Officer

LOS ANGELES, January 03, 2022--CytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development in oncology and neurodegenerative diseases, today announced that it has appointed Dr. Stephen Snowdy to the role of Chief Executive Officer, effective January 10, 2022. Dr. Louis Ignarro succeeded Steven A. Kriegsman as Chairman of the Board of Directors (the "Board") on January 3, 2022.

Yahoo | January 3, 2022

Read More 'CYTR' Stories Here

CYTR Price Returns

1-mo 12.00%
3-mo -70.83%
6-mo -76.66%
1-year -91.19%
3-year -75.00%
5-year -96.80%
YTD -72.28%
2021 -71.14%
2020 503.45%
2019 -35.56%
2018 -73.37%
2017 -23.87%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.1728 seconds.